

## Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

### Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information**  
**Full Analysis Dataset : CHILE**

Number of prospective patients (C1+C2+C3+C4+C5 )	971
Number of enrolling sites	15
Number of enrolling countries	1
Enrolment period	11SEP2012 - 26JUL2016
Duration of enrolment (months)	46.5

**Table 02: Patients by region, country, and cohort  
Full Analysis Dataset : CHILE**

<b>Region</b>	<b>Country</b>	<b>Cohort 2 (N=182)</b>	<b>Cohort 3 (N=318)</b>	<b>Cohort 4 (N=211)</b>	<b>Cohort 5 (N=260)</b>	<b>Total Prospective patients Cohorts 1 to 5 (N=971)</b>	<b>Total Prospective patients Cohorts 1 to 4 (N=711)</b>
Latin America	Chile	182	318	211	260	971	711

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Sex, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Male	103 (56.6)	145 (45.6)	104 (49.3)	142 (54.6)	494 (50.9)	352 (49.5)
	Female	79 (43.4)	173 (54.4)	107 (50.7)	118 (45.4)	477 (49.1)	359 (50.5)
Age at Diagnosis (Years)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Mean (SD)	70.3 (11.2)	72.2 (10.9)	71.4 (11.2)	71.4 (11.6)	71.5 (11.2)	71.5 (11.1)
	Median (IQR)	72.0 (64.0 to 79.0)	73.5 (67.0 to 79.0)	73.0 (64.0 to 79.0)	73.5 (65.0 to 80.0)	73.0 (66.0 to 79.0)	73.0 (66.0 to 79.0)
	Min to Max	35 to 97	22 to 97	29 to 94	34 to 93	22 to 97	22 to 97
Age Group, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	<65	47 (25.8)	59 (18.6)	55 (26.1)	62 (23.8)	223 (23.0)	161 (22.6)
	65-74	63 (34.6)	110 (34.6)	63 (29.9)	75 (28.8)	311 (32.0)	236 (33.2)
	>=75	72 (39.6)	149 (46.9)	93 (44.1)	123 (47.3)	437 (45.0)	314 (44.2)
Time since AF Diagnosis (Weeks)	n (missing)	160 (22)	273 (45)	187 (24)	228 (32)	848 (123)	620 (91)
	Mean (SD)	2.35 (1.79)	2.56 (1.89)	2.27 (1.72)	2.37 (1.78)	2.40 (1.81)	2.42 (1.82)
	Median (IQR)	2.00 (0.80 to 4.00)	2.20 (0.80 to 4.20)	2.10 (0.70 to 3.70)	2.00 (0.80 to 3.80)	2.10 (0.80 to 4.00)	2.10 (0.80 to 4.00)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Caucasian	20 (11.0)	19 (6.0)	7 (3.3)	14 (5.4)	60 (6.2)	46 (6.5)
	Hispanic/Latino	160 (87.9)	298 (93.7)	204 (96.7)	243 (93.5)	905 (93.2)	662 (93.1)
	Asian (Not Chinese)	-	1 (0.3)	-	-	1 (0.1)	1 (0.1)

**Table 03 : Demographic Characteristics  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
	Mixed/Other	2 (1.1)	-	-	3 (1.2)	5 (0.5)	2 (0.3)
Region, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Latin America	182 (100.0)	318 (100.0)	211 (100.0)	260 (100.0)	971 (100.0)	711 (100.0)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Internal Medicine	77 (42.3)	87 (27.4)	51 (24.2)	41 (15.8)	256 (26.4)	215 (30.2)
	Cardiology	57 (31.3)	156 (49.1)	108 (51.2)	143 (55.0)	464 (47.8)	321 (45.1)
	Neurology	5 (2.7)	3 (0.9)	3 (1.4)	4 (1.5)	15 (1.5)	11 (1.5)
	Geriatrics	1 (0.5)	1 (0.3)	-	2 (0.8)	4 (0.4)	2 (0.3)
	Primary Care/General Practice	42 (23.1)	71 (22.3)	49 (23.2)	70 (26.9)	232 (23.9)	162 (22.8)
Care Setting Location at Diagnosis, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Hospital	91 (50.0)	173 (54.4)	109 (51.7)	145 (55.8)	518 (53.3)	373 (52.5)
	Office	33 (18.1)	49 (15.4)	38 (18.0)	59 (22.7)	179 (18.4)	120 (16.9)
	Anticoagulation clinic/thrombosi s centre	1 (0.5)	-	-	-	1 (0.1)	1 (0.1)
	Emergency room	57 (31.3)	96 (30.2)	64 (30.3)	56 (21.5)	273 (28.1)	217 (30.5)
Type of AF Diagnosed, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	Permanent	25 (13.7)	36 (11.3)	14 (6.6)	23 (8.8)	98 (10.1)	75 (10.5)
	Persistent	42 (23.1)	58 (18.2)	47 (22.3)	47 (18.1)	194 (20.0)	147 (20.7)
	Paroxysmal	68 (37.4)	107 (33.6)	53 (25.1)	85 (32.7)	313 (32.2)	228 (32.1)
	New	47 (25.8)	117 (36.8)	97 (46.0)	105 (40.4)	366 (37.7)	261 (36.7)

**Table 04 : Care setting , Type of AF and Insurance  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Treatment Costs, n(%)	n (missing)	182 (0)	284 (0)	183 (0)	240 (0)	889 (0)	649 (0)
	Public insurance	156 (85.7)	258 (90.8)	173 (94.5)	229 (95.4)	816 (91.8)	587 (90.4)
	Private (insurance)	9 (4.9)	17 (6.0)	5 (2.7)	8 (3.3)	39 (4.4)	31 (4.8)
	Private (out of pocket)	5 (2.7)	2 (0.7)	2 (1.1)	-	9 (1.0)	9 (1.4)
	Combination	12 (6.6)	7 (2.5)	3 (1.6)	3 (1.3)	25 (2.8)	22 (3.4)
	Unknown	-	34	28	20	82	62
Treatment Sector, n(%)	n (missing)	182 (0)	313 (0)	211 (0)	257 (0)	963 (0)	706 (0)
	In the public sector	161 (88.5)	260 (83.1)	170 (80.6)	230 (89.5)	821 (85.3)	591 (83.7)
	In the private sector	21 (11.5)	53 (16.9)	41 (19.4)	27 (10.5)	142 (14.7)	115 (16.3)
	Unknown	-	5	-	3	8	5



**Table 05 : Vital signs and life style  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Height (cm)	n (missing)	132 (50)	198 (120)	123 (88)	148 (112)	601 (370)	453 (258)
	Mean (SD)	161.7 (10.2)	160.9 (9.6)	162.0 (9.5)	163.3 (9.7)	161.9 (9.8)	161.4 (9.7)
	Median (IQR)	162.0 (154.0 to 169.0)	160.0 (154.0 to 168.0)	162.0 (155.0 to 168.0)	164.0 (155.5 to 170.0)	162.0 (155.0 to 169.0)	161.0 (154.0 to 168.0)
	Min to Max	138 to 187	139 to 186	142 to 196	145 to 185	138 to 196	138 to 196
Weight (kg)	n (missing)	132 (50)	198 (120)	123 (88)	148 (112)	601 (370)	453 (258)
	Mean (SD)	77.4 (17.8)	74.8 (15.8)	77.0 (19.4)	79.4 (15.9)	77.0 (17.1)	76.2 (17.4)
	Median (IQR)	74.0 (65.5 to 87.0)	73.0 (64.0 to 84.0)	76.0 (64.0 to 86.0)	80.0 (68.0 to 88.0)	75.0 (65.0 to 86.0)	74.0 (64.0 to 85.0)
	Min to Max	44 to 139	40 to 130	45 to 197	44 to 127	40 to 197	40 to 197
BMI (kg/m <sup>2</sup> )	n (missing)	132 (50)	198 (120)	123 (88)	148 (112)	601 (370)	453 (258)
	Mean (SD)	29.6 (5.9)	28.9 (5.3)	29.4 (7.0)	29.8 (5.6)	29.4 (5.9)	29.2 (6.0)
	Median (IQR)	29.0 (25.0 to 33.0)	28.0 (25.0 to 32.0)	29.0 (25.0 to 32.0)	29.0 (26.0 to 33.0)	29.0 (25.0 to 33.0)	29.0 (25.0 to 32.0)
	Min to Max	19 to 51	20 to 50	17 to 75	19 to 54	17 to 75	17 to 75
BMI Category, n(%)	n (missing)	132 (50)	198 (120)	123 (88)	148 (112)	601 (370)	453 (258)
	<19	-	-	3 (2.4)	1 (0.7)	4 (0.7)	3 (0.7)
	19-<25	33 (25.0)	47 (23.7)	28 (22.8)	25 (16.9)	133 (22.1)	108 (23.8)
	25-<30	42 (31.8)	78 (39.4)	43 (35.0)	60 (40.5)	223 (37.1)	163 (36.0)
	30-<40	50 (37.9)	65 (32.8)	41 (33.3)	55 (37.2)	211 (35.1)	156 (34.4)
	>=40	7 (5.3)	8 (4.0)	8 (6.5)	7 (4.7)	30 (5.0)	23 (5.1)
Pulse (bpm)	n (missing)	176 (6)	282 (36)	199 (12)	249 (11)	906 (65)	657 (54)
	Mean (SD)	90.4 (29.3)	88.5 (27.0)	88.9 (26.2)	89.5 (26.3)	89.2 (27.1)	89.1 (27.4)
	Median (IQR)	83.5 (70.0 to 107.5)	82.0 (70.0 to 102.0)	83.0 (69.0 to 100.0)	82.0 (72.0 to 104.0)	82.0 (70.0 to 104.0)	83.0 (70.0 to 104.0)
	Min to Max	42 to 180	40 to 173	52 to 180	44 to 170	40 to 180	40 to 180

**Table 05 : Vital signs and life style  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Systolic BP (mm Hg)	n (missing)	175 (7)	295 (23)	198 (13)	249 (11)	917 (54)	668 (43)
	Mean (SD)	134.0 (21.7)	137.0 (22.3)	135.1 (22.8)	133.3 (20.5)	135.0 (21.9)	135.6 (22.3)
	Median (IQR)	134.0 (120.0 to 148.0)	135.0 (122.0 to 150.0)	134.0 (120.0 to 147.0)	130.0 (120.0 to 146.0)	132.0 (120.0 to 148.0)	134.0 (120.0 to 149.0)
	Min to Max	75 to 213	70 to 212	81 to 208	90 to 204	70 to 213	70 to 213
Diastolic BP (mm Hg)	n (missing)	175 (7)	295 (23)	198 (13)	249 (11)	917 (54)	668 (43)
	Mean (SD)	80.6 (13.8)	79.6 (15.2)	80.0 (14.7)	78.7 (13.8)	79.6 (14.5)	80.0 (14.7)
	Median (IQR)	80.0 (71.0 to 90.0)	79.0 (70.0 to 88.0)	80.0 (70.0 to 90.0)	80.0 (70.0 to 87.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 89.0)
	Min to Max	40 to 125	39 to 144	43 to 138	46 to 130	39 to 144	39 to 144
LVEF (%)	n (missing)	83 (99)	110 (208)	71 (140)	108 (152)	372 (599)	264 (447)
	Mean (SD)	57.6 (13.2)	57.9 (13.2)	59.5 (14.0)	57.9 (14.2)	58.2 (13.6)	58.2 (13.4)
	Median (IQR)	58.0 (50.0 to 68.0)	60.0 (50.0 to 68.0)	61.0 (50.0 to 70.0)	60.5 (50.0 to 68.0)	60.0 (50.0 to 68.0)	60.0 (50.0 to 68.0)
	Min to Max	22 to 79	20 to 80	15 to 87	16 to 78	15 to 87	15 to 87
LVEF Category, n n(%)	n (missing)	83 (99)	110 (208)	71 (140)	108 (152)	372 (599)	264 (447)
	<40%	9 (10.8)	9 (8.2)	5 (7.0)	13 (12.0)	36 (9.7)	23 (8.7)
	>=40%	74 (89.2)	101 (91.8)	66 (93.0)	95 (88.0)	336 (90.3)	241 (91.3)
History of Hypertension, n(%)	n (missing)	182 (0)	317 (0)	211 (0)	259 (0)	969 (0)	710 (0)
	No	22 (12.1)	42 (13.2)	34 (16.1)	42 (16.2)	140 (14.4)	98 (13.8)
	Yes	160 (87.9)	275 (86.8)	177 (83.9)	217 (83.8)	829 (85.6)	612 (86.2)

**Table 05 : Vital signs and life style  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
	Unknown	-	1	-	1	2	1
Alcohol Consumption, n(%)	n (missing)	167 (0)	280 (0)	181 (0)	245 (0)	873 (0)	628 (0)
	Abstinent	106 (63.5)	163 (58.2)	114 (63.0)	155 (63.3)	538 (61.6)	383 (61.0)
	Light	50 (29.9)	98 (35.0)	60 (33.1)	75 (30.6)	283 (32.4)	208 (33.1)
	Moderate	7 (4.2)	11 (3.9)	4 (2.2)	8 (3.3)	30 (3.4)	22 (3.5)
	Heavy	4 (2.4)	8 (2.9)	3 (1.7)	7 (2.9)	22 (2.5)	15 (2.4)
	Unknown	15	38	30	15	98	83
Smoker, n(%)	n (missing)	175 (0)	305 (0)	197 (0)	242 (0)	919 (0)	677 (0)
	No	128 (73.1)	210 (68.9)	140 (71.1)	164 (67.8)	642 (69.9)	478 (70.6)
	Ex-smoker	33 (18.9)	72 (23.6)	43 (21.8)	53 (21.9)	201 (21.9)	148 (21.9)
	Current smoker	14 (8.0)	23 (7.5)	14 (7.1)	25 (10.3)	76 (8.3)	51 (7.5)
	Unknown	7	13	14	18	52	34

**Table 06 : Clinical History**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Congestive heart failure, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	131 (72.0)	259 (81.4)	190 (90.0)	221 (85.0)	801 (82.5)	580 (81.6)
	Yes	51 (28.0)	59 (18.6)	21 (10.0)	39 (15.0)	170 (17.5)	131 (18.4)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	50 (131)	58 (259)	20 (190)	38 (221)	166 (801)	128 (580)
	I	3 (6.0)	11 (19.0)	1 (5.0)	-	15 (9.0)	15 (11.7)
	II	36 (72.0)	27 (46.6)	9 (45.0)	27 (71.1)	99 (59.6)	72 (56.3)
	III	11 (22.0)	15 (25.9)	9 (45.0)	7 (18.4)	42 (25.3)	35 (27.3)
	IV	-	5 (8.6)	1 (5.0)	4 (10.5)	10 (6.0)	6 (4.7)
	Unknown	1	1	1	1	4	3
Coronary artery disease, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	158 (86.8)	274 (86.2)	192 (91.0)	236 (90.8)	860 (88.6)	624 (87.8)
	Yes	24 (13.2)	44 (13.8)	19 (9.0)	24 (9.2)	111 (11.4)	87 (12.2)
Acute coronary syndrome, n(%)	n (missing)	182 (0)	316 (0)	211 (0)	260 (0)	969 (0)	709 (0)
	No	172 (94.5)	291 (92.1)	198 (93.8)	240 (92.3)	901 (93.0)	661 (93.2)
	Yes	10 (5.5)	25 (7.9)	13 (6.2)	20 (7.7)	68 (7.0)	48 (6.8)
	Unknown	-	2	-	-	2	2
Carotid Occlusive Disease, n(%)	n (missing)	181 (0)	317 (0)	211 (0)	260 (0)	969 (0)	709 (0)
	No	177 (97.8)	313 (98.7)	210 (99.5)	257 (98.8)	957 (98.8)	700 (98.7)

**Table 06 : Clinical History**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
	Yes	4 (2.2)	4 (1.3)	1 (0.5)	3 (1.2)	12 (1.2)	9 (1.3)
	Unknown	1	1	-	-	2	2
PE or DVT, n(%)	n (missing)	182 (0)	317 (0)	211 (0)	260 (0)	970 (0)	710 (0)
	No	180 (98.9)	312 (98.4)	208 (98.6)	252 (96.9)	952 (98.1)	700 (98.6)
	Yes	2 (1.1)	5 (1.6)	3 (1.4)	8 (3.1)	18 (1.9)	10 (1.4)
	Unknown	-	1	-	-	1	1
Other Thromboemboli sm, n(%)	n (missing)	180 (2)	0 (318)	0 (211)	0 (260)	180 (791)	180 (531)
	No	178 (98.9)	-	-	-	178 (98.9)	178 (98.9)
	Yes	2 (1.1)	-	-	-	2 (1.1)	2 (1.1)
Systemic Embolization, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	258 (0)	969 (0)	711 (0)
	No	181 (99.5)	312 (98.1)	204 (96.7)	256 (99.2)	953 (98.3)	697 (98.0)
	Yes	1 (0.5)	6 (1.9)	7 (3.3)	2 (0.8)	16 (1.7)	14 (2.0)
	Unknown	-	-	-	2	2	-
Coronary Artery Bypass Graft, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	175 (96.2)	310 (97.5)	206 (97.6)	256 (98.5)	947 (97.5)	691 (97.2)
	Yes	7 (3.8)	8 (2.5)	5 (2.4)	4 (1.5)	24 (2.5)	20 (2.8)
Stroke/TIA, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	165 (90.7)	286 (89.9)	191 (90.5)	236 (90.8)	878 (90.4)	642 (90.3)

**Table 06 : Clinical History**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
	Yes	17 (9.3)	32 (10.1)	20 (9.5)	24 (9.2)	93 (9.6)	69 (9.7)
Stroke, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	170 (93.4)	293 (92.1)	193 (91.5)	241 (92.7)	897 (92.4)	656 (92.3)
	Yes	12 (6.6)	25 (7.9)	18 (8.5)	19 (7.3)	74 (7.6)	55 (7.7)
History of Bleeding, n(%)	n (missing)	182 (0)	317 (0)	211 (0)	260 (0)	970 (0)	710 (0)
	No	175 (96.2)	306 (96.5)	208 (98.6)	255 (98.1)	944 (97.3)	689 (97.0)
	Yes	7 (3.8)	11 (3.5)	3 (1.4)	5 (1.9)	26 (2.7)	21 (3.0)
	Unknown	-	1	-	-	1	1
Hypercholester olaemia, n(%)	n (missing)	182 (0)	281 (0)	192 (0)	231 (0)	886 (0)	655 (0)
	No	114 (62.6)	159 (56.6)	120 (62.5)	138 (59.7)	531 (59.9)	393 (60.0)
	Yes	68 (37.4)	122 (43.4)	72 (37.5)	93 (40.3)	355 (40.1)	262 (40.0)
	Unknown	-	37	19	29	85	56
Diabetes, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	134 (73.6)	238 (74.8)	169 (80.1)	183 (70.4)	724 (74.6)	541 (76.1)
	Type I	-	6 (1.9)	2 (0.9)	10 (3.8)	18 (1.9)	8 (1.1)
	Type II	48 (26.4)	74 (23.3)	40 (19.0)	67 (25.8)	229 (23.6)	162 (22.8)
Diabetes, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	134 (73.6)	238 (74.8)	169 (80.1)	183 (70.4)	724 (74.6)	541 (76.1)
	Yes	48 (26.4)	80 (25.2)	42 (19.9)	77 (29.6)	247 (25.4)	170 (23.9)
Cirrhosis, n(%)	n (missing)	182 (0)	315 (0)	210 (0)	259 (0)	966 (0)	707 (0)
	No	181 (99.5)	313 (99.4)	210 (100.0)	258 (99.6)	962 (99.6)	704 (99.6)
	Yes	1 (0.5)	2 (0.6)	-	1 (0.4)	4 (0.4)	3 (0.4)
	Unknown	-	3	1	1	5	4

**Table 06 : Clinical History**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Dementia, n(%)	n (missing)	182 (0)	317 (0)	211 (0)	260 (0)	970 (0)	710 (0)
	No	182 (100.0)	313 (98.7)	208 (98.6)	259 (99.6)	962 (99.2)	703 (99.0)
	Yes	-	4 (1.3)	3 (1.4)	1 (0.4)	8 (0.8)	7 (1.0)
	Unknown	-	1	-	-	1	1
Hyperthyroidism, n(%)	n (missing)	182 (0)	314 (0)	210 (0)	259 (0)	965 (0)	706 (0)
	No	182 (100.0)	313 (99.7)	210 (100.0)	258 (99.6)	963 (99.8)	705 (99.9)
	Yes	-	1 (0.3)	-	1 (0.4)	2 (0.2)	1 (0.1)
	Unknown	-	4	1	1	6	5
Hypothyroidism, n(%)	n (missing)	182 (0)	313 (0)	210 (0)	259 (0)	964 (0)	705 (0)
	No	168 (92.3)	276 (88.2)	191 (91.0)	230 (88.8)	865 (89.7)	635 (90.1)
	Yes	14 (7.7)	37 (11.8)	19 (9.0)	29 (11.2)	99 (10.3)	70 (9.9)
	Unknown	-	5	1	1	7	6
Vascular Disease, n(%)	n (missing)	182 (0)	317 (1)	211 (0)	260 (0)	970 (1)	710 (1)
	No	164 (90.1)	283 (89.3)	194 (91.9)	238 (91.5)	879 (90.6)	641 (90.3)
	Yes	18 (9.9)	34 (10.7)	17 (8.1)	22 (8.5)	91 (9.4)	69 (9.7)
Moderate to Severe CKD, n(%)	n (missing)	182 (0)	318 (0)	211 (0)	260 (0)	971 (0)	711 (0)
	No	162 (89.0)	297 (93.4)	203 (96.2)	248 (95.4)	910 (93.7)	662 (93.1)
	Yes	20 (11.0)	21 (6.6)	8 (3.8)	12 (4.6)	61 (6.3)	49 (6.9)

**Table 07 : Treatment for stroke prophylaxis  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
Baseline Treatment, n(%)	n (missing)	181 (0)	315 (0)	211 (0)	254 (0)	961 (0)	707 (0)
	VKA	86 (47.5)	171 (54.3)	117 (55.5)	145 (57.1)	519 (54.0)	374 (52.9)
	VKA+AP	31 (17.1)	47 (14.9)	37 (17.5)	41 (16.1)	156 (16.2)	115 (16.3)
	FXA	7 (3.9)	18 (5.7)	17 (8.1)	19 (7.5)	61 (6.3)	42 (5.9)
	FXA+AP	3 (1.7)	10 (3.2)	9 (4.3)	9 (3.5)	31 (3.2)	22 (3.1)
	DTI	4 (2.2)	5 (1.6)	3 (1.4)	4 (1.6)	16 (1.7)	12 (1.7)
	DTI+AP	1 (0.6)	2 (0.6)	-	2 (0.8)	5 (0.5)	3 (0.4)
	AP	23 (12.7)	37 (11.7)	14 (6.6)	25 (9.8)	99 (10.3)	74 (10.5)
	NONE	26 (14.4)	25 (7.9)	14 (6.6)	9 (3.5)	74 (7.7)	65 (9.2)
	Unknown	1	3	-	6	10	4
	VKA±AP	117 (64.6)	218 (69.2)	154 (73.0)	186 (73.2)	675 (70.2)	489 (69.2)
	FXA±AP	10 (5.5)	28 (8.9)	26 (12.3)	28 (11.0)	92 (9.6)	64 (9.1)
	DTI±AP	5 (2.8)	7 (2.2)	3 (1.4)	6 (2.4)	21 (2.2)	15 (2.1)
	FXA/DTI	11 (6.1)	23 (7.3)	20 (9.5)	23 (9.1)	77 (8.0)	54 (7.6)
	FXA/DTI+AP	4 (2.2)	12 (3.8)	9 (4.3)	11 (4.3)	36 (3.7)	25 (3.5)
	FXA/DTI±AP	15 (8.3)	35 (11.1)	29 (13.7)	34 (13.4)	113 (11.8)	79 (11.2)
	AC	97 (53.6)	194 (61.6)	137 (64.9)	168 (66.1)	596 (62.0)	428 (60.5)
	AC+AP	35 (19.3)	59 (18.7)	46 (21.8)	52 (20.5)	192 (20.0)	140 (19.8)
	AC±AP	132 (72.9)	253 (80.3)	183 (86.7)	220 (86.6)	788 (82.0)	568 (80.3)



**Table 08: Treatment**  
**Full Analysis Dataset : CHILE**

	<b>Cohort 2</b> <b>(N=182)</b> <b>(n %)</b>	<b>Cohort 3</b> <b>(N=318)</b> <b>(n %)</b>	<b>Cohort 4</b> <b>(N=211)</b> <b>(n %)</b>	<b>Cohort 5</b> <b>(N=260)</b> <b>(n %)</b>	<b>Total</b> <b>Prospective</b> <b>patients</b> <b>Cohorts 1 to 5</b> <b>(N=971)</b>	<b>Total</b> <b>Prospective</b> <b>patients</b> <b>Cohorts 1 to 4</b> <b>(N=711)</b>
<b>Anti-platelet (non mutually exclusive groups)</b>						
Glycoprotein inhibitors	1 (0.5)	-	-		1 (0.1)	1 (0.1)
ADP receptor/P2Y12 inhibitors	8 (4.4)	10 (3.1)	5 (2.4)	4 (1.5)	27 (2.8)	23 (3.2)
Prostaglandin Cox inhibitors	1 (0.5)	-	-		1 (0.1)	1 (0.1)
ASA	1 (0.5)	7 (2.2)	1 (0.5)	2 (0.8)	11 (1.1)	9 (1.3)
	51 (28.0)	88 (27.7)	56 (26.5)	57 (21.9)	252 (26.0)	195 (27.4)
<b>Anticoagulant drugs (non mutually exclusive groups)</b>						
VKA	117 (64.3)	221 (69.5)	154 (73.0)	192 (73.8)	684 (70.4)	492 (69.2)
FXa	10 (5.5)	30 (9.4)	26 (12.3)	34 (13.1)	100 (10.3)	66 (9.3)
DTI	5 (2.7)	8 (2.5)	3 (1.4)	6 (2.3)	22 (2.3)	16 (2.3)
Heparinoid	5 (2.7)	-	1 (0.5)	1 (0.4)	7 (0.7)	6 (0.8)
Heparins	21 (11.5)	46 (14.5)	21 (10.0)	17 (6.5)	105 (10.8)	88 (12.4)

**Table 09 : Risk scores**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
CHADS2 Score	n (missing)	179 (3)	317 (1)	207 (4)	258 (2)	961 (10)	703 (8)
	Mean (SD)	2.1 (1.1)	2.0 (1.1)	1.8 (1.1)	2.0 (1.2)	2.0 (1.1)	2.0 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 6	0 to 6	0 to 5	0 to 5	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	179 (3)	317 (1)	207 (4)	258 (2)	961 (10)	703 (8)
	0	6 (3.4)	16 (5.0)	19 (9.2)	19 (7.4)	60 (6.2)	41 (5.8)
	1	56 (31.3)	90 (28.4)	66 (31.9)	75 (29.1)	287 (29.9)	212 (30.2)
	2	66 (36.9)	125 (39.4)	75 (36.2)	93 (36.0)	359 (37.4)	266 (37.8)
	3	33 (18.4)	54 (17.0)	32 (15.5)	41 (15.9)	160 (16.6)	119 (16.9)
	4	11 (6.1)	25 (7.9)	13 (6.3)	24 (9.3)	73 (7.6)	49 (7.0)
	5	5 (2.8)	6 (1.9)	2 (1.0)	6 (2.3)	19 (2.0)	13 (1.8)
	6	2 (1.1)	1 (0.3)	-	-	3 (0.3)	3 (0.4)
CHA2DS2- VASc Score	n (missing)	179 (3)	316 (2)	207 (4)	256 (4)	958 (13)	702 (9)
	Mean (SD)	3.4 (1.6)	3.5 (1.5)	3.2 (1.5)	3.3 (1.6)	3.3 (1.5)	3.4 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	4.0 (3.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 7	0 to 7	0 to 8	0 to 8
CHA2DS2- VASc score categories, n(%)	n (missing)	179 (3)	316 (2)	207 (4)	256 (4)	958 (13)	702 (9)
	0	4 (2.2)	5 (1.6)	10 (4.8)	10 (3.9)	29 (3.0)	19 (2.7)
	1	19 (10.6)	24 (7.6)	23 (11.1)	29 (11.3)	95 (9.9)	66 (9.4)
	2	31 (17.3)	44 (13.9)	35 (16.9)	40 (15.6)	150 (15.7)	110 (15.7)
	3	45 (25.1)	75 (23.7)	47 (22.7)	59 (23.0)	226 (23.6)	167 (23.8)
	4	38 (21.2)	103 (32.6)	54 (26.1)	66 (25.8)	261 (27.2)	195 (27.8)

**Table 09 : Risk scores**  
**Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=182) (n %)	Cohort 3 (N=318) (n %)	Cohort 4 (N=211) (n %)	Cohort 5 (N=260) (n %)	Total Prospective patients Cohorts 1 to 5 (N=971)	Total Prospective patients Cohorts 1 to 4 (N=711)
	5	26 (14.5)	41 (13.0)	26 (12.6)	26 (10.2)	119 (12.4)	93 (13.2)
	6-9	16 (8.9)	24 (7.6)	12 (5.8)	26 (10.2)	78 (8.1)	52 (7.4)
HAS-BLED score	n (missing)	115 (67)	226 (92)	149 (62)	211 (49)	701 (270)	490 (221)
	Mean (SD)	1.5 (0.9)	1.6 (0.9)	1.4 (0.8)	1.4 (0.8)	1.5 (0.8)	1.5 (0.9)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 6	0 to 5	0 to 3	0 to 4	0 to 6	0 to 6
HAS-BLED score categories, n(%)	n (missing)	115 (67)	226 (92)	149 (62)	211 (49)	701 (270)	490 (221)
	0	9 (7.8)	12 (5.3)	15 (10.1)	24 (11.4)	60 (8.6)	36 (7.3)
	1	55 (47.8)	102 (45.1)	71 (47.7)	103 (48.8)	331 (47.2)	228 (46.5)
	2	35 (30.4)	80 (35.4)	51 (34.2)	69 (32.7)	235 (33.5)	166 (33.9)
	3	15 (13.0)	28 (12.4)	12 (8.1)	14 (6.6)	69 (9.8)	55 (11.2)
	4	-	3 (1.3)	-	1 (0.5)	4 (0.6)	3 (0.6)
	5	-	1 (0.4)	-	-	1 (0.1)	1 (0.2)
	6-9	1 (0.9)	-	-	-	1 (0.1)	1 (0.2)

**Table 10: Treatment at baseline by CHA2DS2-VASc score**  
**Full Analysis Dataset : CHILE**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	1	25	-	-	1	25	-	-	-	-	-	-	-	-	2	50	-
	1	11	57.9	1	5.3	1	5.3	-	-	-	-	-	-	5	26.3	1	5.3	-
	2	9	29	8	25.8	2	6.5	1	3.2	1	3.2	1	3.2	6	19.4	3	9.7	-
	3	19	42.2	10	22.2	2	4.4	-	-	-	-	-	-	4	8.9	10	22.2	-
	4	22	59.5	4	10.8	-	-	-	-	-	-	-	-	7	18.9	4	10.8	1
	5	15	57.7	4	15.4	-	-	2	7.7	1	3.8	-	-	1	3.8	3	11.5	-
	6-9	8	50	2	12.5	1	6.3	-	-	2	12.5	-	-	-	-	3	18.8	-
Cohort 3	0	-	-	-	-	-	-	1	20	-	-	-	-	1	20	3	60	-
	1	11	45.8	1	4.2	-	-	-	-	-	-	1	4.2	7	29.2	4	16.7	-
	2	26	59.1	4	9.1	1	2.3	-	-	1	2.3	-	-	9	20.5	3	6.8	-
	3	44	59.5	10	13.5	7	9.5	3	4.1	1	1.4	-	-	4	5.4	5	6.8	1
	4	56	54.9	17	16.7	5	4.9	6	5.9	2	2	1	1	9	8.8	6	5.9	1
	5	24	58.5	8	19.5	1	2.4	-	-	1	2.4	-	-	4	9.8	3	7.3	-
	6-9	9	39.1	7	30.4	4	17.4	-	-	-	-	-	-	2	8.7	1	4.3	1
Cohort 4	0	2	20	2	20	1	10	-	-	-	-	-	-	2	20	3	30	-
	1	7	30.4	4	17.4	2	8.7	1	4.3	1	4.3	-	-	5	21.7	3	13	-
	2	21	60	5	14.3	4	11.4	2	5.7	-	-	-	-	2	5.7	1	2.9	-
	3	22	46.8	9	19.1	6	12.8	2	4.3	-	-	-	-	4	8.5	4	8.5	-
	4	39	72.2	8	14.8	1	1.9	3	5.6	1	1.9	-	-	-	-	2	3.7	-
	5	14	53.8	6	23.1	2	7.7	1	3.8	1	3.8	-	-	1	3.8	1	3.8	-
	6-9	9	75	2	16.7	1	8.3	-	-	-	-	-	-	-	-	-	-	-
Cohort 5	0	2	20	2	20	-	-	1	10	-	-	-	-	3	30	2	20	-
	1	11	37.9	2	6.9	4	13.8	1	3.4	-	-	-	-	8	27.6	3	10.3	-
	2	23	60.5	7	18.4	3	7.9	3	7.9	1	2.6	-	-	1	2.6	-	-	2
	3	40	67.8	10	16.9	2	3.4	-	-	-	-	-	-	6	10.2	1	1.7	-
	4	38	60.3	11	17.5	4	6.3	2	3.2	1	1.6	2	3.2	4	6.3	1	1.6	3
	5	17	65.4	3	11.5	3	11.5	-	-	2	7.7	-	-	1	3.8	-	-	-
	6-9	11	44	6	24	3	12	2	8	-	-	-	-	2	8	1	4	1

**Table 10: Treatment at baseline by CHA2DS2-VASc score  
Full Analysis Dataset : CHILE**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	5	17.2	4	13.8	2	6.9	2	6.9	-	-	-	-	6	20.7	10	34.5	-
	1	40	42.1	8	8.4	7	7.4	2	2.1	1	1.1	1	1.1	25	26.3	11	11.6	-
	2	79	53.4	24	16.2	10	6.8	6	4.1	3	2	1	0.7	18	12.2	7	4.7	2
	3	125	55.6	39	17.3	17	7.6	5	2.2	1	0.4	-	-	18	8	20	8.9	1
	4	155	60.5	40	15.6	10	3.9	11	4.3	4	1.6	3	1.2	20	7.8	13	5.1	5
	5	70	58.8	21	17.6	6	5	3	2.5	5	4.2	-	-	7	5.9	7	5.9	-
	6-9	37	48.7	17	22.4	9	11.8	2	2.6	2	2.6	-	-	4	5.3	5	6.6	2
Total Prospective patients Cohorts 1 to 4	0	3	15.8	2	10.5	2	10.5	1	5.3	-	-	-	-	3	15.8	8	42.1	-
	1	29	43.9	6	9.1	3	4.5	1	1.5	1	1.5	1	1.5	17	25.8	8	12.1	-
	2	56	50.9	17	15.5	7	6.4	3	2.7	2	1.8	1	0.9	17	15.5	7	6.4	-
	3	85	51.2	29	17.5	15	9	5	3	1	0.6	-	-	12	7.2	19	11.4	1
	4	117	60.6	29	15	6	3.1	9	4.7	3	1.6	1	0.5	16	8.3	12	6.2	2
	5	53	57	18	19.4	3	3.2	3	3.2	3	3.2	-	-	6	6.5	7	7.5	-
	6-9	26	51	11	21.6	6	11.8	-	-	2	3.9	-	-	2	3.9	4	7.8	1

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : CHILE**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	7	77.8	-	-	1	11.1	-	-	-	-	-	-	-	-	1	11.1	-
	1	31	56.4	4	7.3	4	7.3	-	-	1	1.8	-	-	5	9.1	10	18.2	-
	2	9	25.7	10	28.6	1	2.9	2	5.7	-	-	-	-	7	20	6	17.1	-
	3	5	33.3	5	33.3	-	-	-	-	-	-	-	-	4	26.7	1	6.7	-
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100	-
Cohort 3	0	6	50	-	-	1	8.3	-	-	-	-	-	-	-	-	5	41.7	-
	1	72	71.3	5	5	8	7.9	1	1	1	1	1	1	9	8.9	4	4	1
	2	31	38.8	23	28.8	4	5	4	5	2	2.5	1	1.3	9	11.3	6	7.5	-
	3	8	29.6	11	40.7	1	3.7	-	-	-	-	-	-	6	22.2	1	3.7	1
	4-9	1	25	1	25	-	-	-	-	-	-	-	-	2	50	-	-	-
Cohort 4	0	8	53.3	-	-	2	13.3	-	-	1	6.7	-	-	-	-	4	26.7	-
	1	48	67.6	6	8.5	6	8.5	1	1.4	1	1.4	-	-	6	8.5	3	4.2	-
	2	23	45.1	13	25.5	3	5.9	2	3.9	1	2	-	-	4	7.8	5	9.8	-
	3	6	50	4	33.3	1	8.3	-	-	-	-	-	-	1	8.3	-	-	-
Cohort 5	0	18	75	-	-	3	12.5	-	-	-	-	-	-	-	-	3	12.5	-
	1	72	70.6	6	5.9	8	7.8	3	2.9	1	1	-	-	8	7.8	4	3.9	1
	2	22	33.8	18	27.7	3	4.6	4	6.2	3	4.6	2	3.1	12	18.5	1	1.5	4
	3	4	30.8	4	30.8	1	7.7	2	15.4	-	-	-	-	1	7.7	1	7.7	1
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	1	100	-	-	-
Total Prospective patients Cohorts 1 to 5	0	39	65	-	-	7	11.7	-	-	1	1.7	-	-	-	-	13	21.7	-
	1	223	67.8	21	6.4	26	7.9	5	1.5	4	1.2	1	0.3	28	8.5	21	6.4	2
	2	85	36.8	64	27.7	11	4.8	12	5.2	6	2.6	3	1.3	32	13.9	18	7.8	4
	3	23	34.3	24	35.8	3	4.5	2	3	-	-	-	-	12	17.9	3	4.5	2
	4-9	1	16.7	1	16.7	-	-	-	-	-	-	-	-	3	50	1	16.7	-

**Table 11: Treatment at baseline by HAS-BLED score  
Full Analysis Dataset : CHILE**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total	0	21	58.3	-	-	4	11.1	-	-	1	2.8	-	-	-	-	10	27.8	-
Prospective patients																		
Cohorts 1 to 4																		
	1	151	66.5	15	6.6	18	7.9	2	0.9	3	1.3	1	0.4	20	8.8	17	7.5	1
	2	63	38	46	27.7	8	4.8	8	4.8	3	1.8	1	0.6	20	12	17	10.2	-
	3	19	35.2	20	37	2	3.7	-	-	-	-	-	-	11	20.4	2	3.7	1
	4-9	1	20	1	20	-	-	-	-	-	-	-	-	2	40	1	20	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

Variable	Statistics	Cohort 2 (N=117) (n %)	Cohort 3 (N=218) (n %)	Cohort 4 (N=154) (n %)	Total Prospective patients Cohorts 1 to 4 (N=489)
TTR value, n(%)	n (missing)	74 (43)	149 (69)	104 (50)	327 (162)
	<65	63 (85.1)	131 (87.9)	79 (76.0)	273 (83.5)
	>=65	11 (14.9)	18 (12.1)	25 (24.0)	54 (16.5)
TTR	n (missing)	74 (43)	149 (69)	104 (50)	327 (162)
	Mean (SD)	37.9 (21.3)	40.4 (21.1)	43.0 (25.1)	40.7 (22.5)
	Median (IQR)	36.7 (20.2 to 50.6)	41.9 (25.4 to 53.5)	42.3 (22.8 to 63.8)	40.8 (23.0 to 54.8)
	Min to Max	0.0 to 87.8	0.0 to 100.0	0.0 to 92.3	0.0 to 100.0
INR value, n(%)	n	1008	1740	1101	3849
	2-3	334 (33.1)	607 (34.9)	428 (38.9)	1369 (35.6)
	<2	537 (53.3)	896 (51.5)	497 (45.1)	1930 (50.1)
	>3	137 (13.6)	237 (13.6)	176 (16.0)	550 (14.3)
INR	n	1008	1740	1101	3849
	Mean (SD)	2.2 (1.1)	2.2 (1.0)	2.3 (1.1)	2.2 (1.1)
	Median (IQR)	1.9 (1.5 to 2.5)	2.0 (1.5 to 2.5)	2.1 (1.7 to 2.7)	2.0 (1.6 to 2.6)
	Min to Max	0.9 to 12.3	0.8 to 10.0	0.9 to 13.9	0.8 to 13.9



**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		711	32	4.75	(3.36 to 6.71)
	<b>Cardiovascular death</b>	711	17	2.52	(1.57 to 4.06)
	<b>Non-Cardiovascular death</b>	711	12	1.78	(1.01 to 3.14)
	<b>Undetermined cause</b>	711	3	0.45	(0.14 to 1.38)
Stroke/SE		711	16	2.40	(1.47 to 3.92)
Major bleed		711	11	1.64	(0.91 to 2.97)
Acute coronary syndrome		711	5	0.74	(0.31 to 1.78)
Congestive Heart Failure		711	5	0.75	(0.31 to 1.79)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

		CHILE		
Outcome	Cause	N	Events	%
<b>Cardiovascular causes</b>	Myocardial infarction	17	1	5.88
	Congestive heart failure	17	4	23.53
	Sudden or unwitnessed death	17	3	17.65
	Other	17	9	52.94
<b>Non-cardiovascular causes</b>	Respiratory failure	12	2	16.67
	Infection/sepsis	12	2	16.67
	Malignancy	12	3	25.00
	Other	12	5	41.67

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset :CHILE**

OUTCOME	CHILE		
	N	Events	%
Stroke(not including systemic embolism)	711	14	1.97
Primary Ischemic Stroke	711	8	1.13
<i>of which secondary hemorrhagic     ischemic</i>	711	2	0.28
<b>Primary intracerebral hemorrhage*</b>	711	6	0.84
<i>Intracerebral</i>	711	4	0.56
<i>Subarachnoid</i>	711	1	0.14
<i>Intraventricular</i>	711	1	0.14

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	19	17.80	1	5.62	(0.79 to 39.89)
1	66	63.92	0	-	-
2	110	105.06	6	5.71	(2.57 to 12.71)
3	167	158.05	4	2.53	(0.95 to 6.74)
4+	340	320.80	20	6.23	(4.02 to 9.66)
Unknown	9	8.46	1	11.82	(1.67 to 83.89)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	19	17.80	1	5.62	(0.79 to 39.89)
1	66	63.92	0	-	-
2	110	103.49	4	3.87	(1.45 to 10.30)
3	167	155.93	3	1.92	(0.62 to 5.97)
4+	340	317.12	7	2.21	(1.05 to 4.63)
Unknown	9	8.44	1	11.84	(1.67 to 84.08)

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4  
Full Analysis Dataset : CHILE**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	19	17.80	1	5.62	(0.79 to 39.89)
1	66	63.50	1	1.58	(0.22 to 11.18)
2	110	104.68	2	1.91	(0.48 to 7.64)
3	167	157.12	1	0.64	(0.09 to 4.52)
4+	340	318.11	5	1.57	(0.65 to 3.78)
Unknown	9	8.44	1	11.84	(1.67 to 84.08)